HRP20211013T1 - Antagonisti receptora cgrp - Google Patents
Antagonisti receptora cgrp Download PDFInfo
- Publication number
- HRP20211013T1 HRP20211013T1 HRP20211013TT HRP20211013T HRP20211013T1 HR P20211013 T1 HRP20211013 T1 HR P20211013T1 HR P20211013T T HRP20211013T T HR P20211013TT HR P20211013 T HRP20211013 T HR P20211013T HR P20211013 T1 HRP20211013 T1 HR P20211013T1
- Authority
- HR
- Croatia
- Prior art keywords
- compound
- salt according
- image
- salt
- pharmaceutically acceptable
- Prior art date
Links
- 108010078311 Calcitonin Gene-Related Peptide Receptors Proteins 0.000 title 1
- 102000008323 calcitonin gene-related peptide receptor activity proteins Human genes 0.000 title 1
- 239000002464 receptor antagonist Substances 0.000 title 1
- 229940044551 receptor antagonist Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 19
- 150000003839 salts Chemical class 0.000 claims 16
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 2
- 208000019695 Migraine disease Diseases 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 206010027599 migraine Diseases 0.000 claims 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 2
- 230000005855 radiation Effects 0.000 claims 2
- 238000001228 spectrum Methods 0.000 claims 2
- 238000002441 X-ray diffraction Methods 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
- C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C309/04—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing only one sulfo group
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Claims (18)
1. Spoj formule:
[image]
,
naznačen time što
Y je CH ili N;
Z je CH ili N;
uz uvjet da kada je Y CH, Z je N, a kada je Y N, Z je CH;
X je CH ili N; i
R je C1-C3 alkil, C3-C5 cikloalkil ili CN,
ili njegova farmaceutski prihvatljiva sol.
2. Spoj ili sol u skladu s patentnim zahtjevom 1, naznačen time što je X CH.
3. Spoj ili sol u skladu s bilo patentnim zahtjevom 1 ili patentnim zahtjevom 2, naznačen time što je Y CH, a Z je N.
4. Spoj ili sol u skladu s bilo kojim od patentnih zahtjeva 1 do 3, naznačen time što je R C1-C3 alkil.
5. Spoj ili sol u skladu s bilo kojim od patentnih zahtjeva 1 do 4, naznačen time što ima Formulu:
[image]
.
6. Spoj ili sol u skladu s bilo kojim od patentnih zahtjeva 1 do 5, naznačen time što ima Formulu:
[image]
.
7. Spoj ili sol u skladu s patentnim zahtjevom 1, naznačen time što je spoj:
[image]
.
8. Spoj ili sol u skladu s patentnim zahtjevom 7, naznačen time što je spoj:
[image]
.
9. Spoj ili sol u skladu s patentnim zahtjevom 8, naznačen time što je spoj:
[image]
.
10. Spoj u skladu s patentnim zahtjevom 9, naznačena time što je:
[image]
.
11. Spoj u skladu s patentnim zahtjevom 10 koji je kristalni anhidrat, naznačen time što ima značajan maksimum u difrakcijskom spektru rendgenskih zraka pod difrakcijskim kutem 2θ od 13,4°, u kombinaciji s jednim ili više maksimuma koje se bira iz skupine koju čine 14,4°, 18,1°, 19,4°, 20,9°, 21,2°, 21,5° i 26,5°, uz toleranciju za difrakcijske kuteve od 0,2, što je izmjereno uz pomoć izvora CuKα zračenja.
12. Sol u skladu s patentnim zahtjevom 9, naznačena time što je:
[image]
.
13. Sol u skladu s patentnim zahtjevom 12 koja je kristalna, naznačena time što ima značajan maksimum u difrakcijskom spektru rendgenskih zraka pod difrakcijskim kutem 2θ od at 18.8° u kombinaciji s jednim ili više maksimuma koje se bira iz skupine koju čine 23,2°, 24,7°, te 15,2°; uz toleranciju za difrakcijske kutove od 0,2 stupnjeva, što je izmjereno uz pomoć izvora CuKα zračenja.
14. Spoj ili sol u skladu s bilo kojim od patentnih zahtjeva 1-13, naznačen time što je namijenjen upotrebi u terapiji.
15. Spoj ili sol u skladu s bilo kojim od patentnih zahtjeva 1-13, naznačen time što je namijenjen upotrebi u liječenju migrene.
16. Spoj ili sol u skladu s bilo kojim od patentnih zahtjeva 1-13, naznačen time što je namijenjen upotrebi u sprječavanju migrene.
17. Farmaceutski pripravak, naznačen time što sadrži spoj ili sol u skladu s bilo kojim od patentnih zahtjeva 1-13 uz jedan ili više farmaceutski prihvatljivih nosača, razrjeđivača ili pomoćnih sredstava.
18. Postupak priprave farmaceutskog pripravka, naznačen time što se sastoji u miješanju spoja ili soli u skladu s bilo kojim od patentnih zahtjeva 1-13 uz jedan ili više farmaceutski prihvatljivih nosača, razrjeđivača ili pomoćnih sredstava.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562203996P | 2015-08-12 | 2015-08-12 | |
| US201562266867P | 2015-12-14 | 2015-12-14 | |
| EP16751123.7A EP3334721B1 (en) | 2015-08-12 | 2016-08-05 | Cgrp receptor antagonists |
| PCT/US2016/045698 WO2017027345A1 (en) | 2015-08-12 | 2016-08-05 | Cgrp receptor antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20211013T1 true HRP20211013T1 (hr) | 2021-10-01 |
Family
ID=56684300
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20211013TT HRP20211013T1 (hr) | 2015-08-12 | 2021-06-28 | Antagonisti receptora cgrp |
Country Status (36)
| Country | Link |
|---|---|
| US (1) | US9708297B2 (hr) |
| EP (1) | EP3334721B1 (hr) |
| JP (1) | JP6619503B2 (hr) |
| KR (1) | KR20180030582A (hr) |
| CN (1) | CN107922385B (hr) |
| AU (1) | AU2016304769B2 (hr) |
| BR (1) | BR112018000513A2 (hr) |
| CA (1) | CA2992622A1 (hr) |
| CL (1) | CL2018000290A1 (hr) |
| CO (1) | CO2018001383A2 (hr) |
| CR (1) | CR20180043A (hr) |
| CY (1) | CY1124413T1 (hr) |
| DK (1) | DK3334721T3 (hr) |
| DO (1) | DOP2018000042A (hr) |
| EA (1) | EA201890156A1 (hr) |
| EC (1) | ECSP18009366A (hr) |
| ES (1) | ES2875600T3 (hr) |
| HK (1) | HK1249095A1 (hr) |
| HR (1) | HRP20211013T1 (hr) |
| HU (1) | HUE055609T2 (hr) |
| IL (1) | IL256572A (hr) |
| LT (1) | LT3334721T (hr) |
| MD (1) | MD3334721T2 (hr) |
| MX (1) | MX2018001672A (hr) |
| NZ (1) | NZ738990A (hr) |
| PE (1) | PE20180655A1 (hr) |
| PH (1) | PH12018500282A1 (hr) |
| PL (1) | PL3334721T3 (hr) |
| PT (1) | PT3334721T (hr) |
| RS (1) | RS62041B1 (hr) |
| SI (1) | SI3334721T1 (hr) |
| SV (1) | SV2018005631A (hr) |
| TN (1) | TN2018000026A1 (hr) |
| TW (1) | TWI636041B (hr) |
| WO (1) | WO2017027345A1 (hr) |
| ZA (1) | ZA201800452B (hr) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201904955A (zh) * | 2017-05-15 | 2019-02-01 | 美商美國禮來大藥廠 | 可作為cgrp受體拮抗劑之3-甲基-吡咯啶-2,5-二酮衍生物 |
| US11066386B2 (en) | 2017-05-15 | 2021-07-20 | Eli Lilly And Company | CGRP receptor antagonists |
| WO2019112024A1 (ja) * | 2017-12-08 | 2019-06-13 | キッセイ薬品工業株式会社 | ピロリジン化合物 |
| WO2020153414A1 (ja) | 2019-01-24 | 2020-07-30 | 武田薬品工業株式会社 | 複素環化合物及びその用途 |
| JP2021050161A (ja) | 2019-09-25 | 2021-04-01 | 武田薬品工業株式会社 | 複素環化合物及びその用途 |
| US20230096051A1 (en) * | 2019-12-12 | 2023-03-30 | Eli Lilly And Company | Cgrp antigonists useful as tracer compounds for positron emission tomography |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998015550A1 (en) * | 1996-10-04 | 1998-04-16 | Novo Nordisk A/S | N-substituted azaheterocyclic compounds |
| US6680387B2 (en) | 2000-04-24 | 2004-01-20 | Aryx Therapeutics | Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis |
| JP2009539800A (ja) * | 2006-06-08 | 2009-11-19 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｃｇｒｐ拮抗薬による胃腸障害の治療 |
| JP2010521457A (ja) * | 2007-03-12 | 2010-06-24 | メルク・シャープ・エンド・ドーム・コーポレイション | 単環式アニリドスピロラクタムｃｇｒｐ受容体アンタゴニスト |
| EP2685826B1 (en) * | 2011-03-18 | 2016-02-03 | Merck Sharp & Dohme Corp. | Piperidinone carboxamide spirohydantoin cgrp receptor antagonists |
| EP2846798B1 (en) * | 2012-05-09 | 2018-04-04 | Merck Sharp & Dohme Corp. | Aliphatic spirolactam cgrp receptor antagonists |
| FR3009961A1 (fr) * | 2013-08-30 | 2015-03-06 | Ct Hospitalier Universitaire De Clermont Fd | Agent bloqueur des canaux cav3 dans le traitement de la douleur |
| WO2015161011A1 (en) * | 2014-04-17 | 2015-10-22 | Merck Sharp & Dohme Corp. | Benzamide cgrp receptor antagonists |
-
2016
- 2016-07-27 TW TW105123799A patent/TWI636041B/zh not_active IP Right Cessation
- 2016-08-05 ES ES16751123T patent/ES2875600T3/es active Active
- 2016-08-05 MD MDE20180605T patent/MD3334721T2/ro unknown
- 2016-08-05 SI SI201631181T patent/SI3334721T1/sl unknown
- 2016-08-05 HU HUE16751123A patent/HUE055609T2/hu unknown
- 2016-08-05 PL PL16751123T patent/PL3334721T3/pl unknown
- 2016-08-05 JP JP2018507584A patent/JP6619503B2/ja active Active
- 2016-08-05 EP EP16751123.7A patent/EP3334721B1/en active Active
- 2016-08-05 CR CR20180043A patent/CR20180043A/es unknown
- 2016-08-05 KR KR1020187003726A patent/KR20180030582A/ko not_active Application Discontinuation
- 2016-08-05 MX MX2018001672A patent/MX2018001672A/es unknown
- 2016-08-05 WO PCT/US2016/045698 patent/WO2017027345A1/en active Application Filing
- 2016-08-05 DK DK16751123.7T patent/DK3334721T3/da active
- 2016-08-05 CA CA2992622A patent/CA2992622A1/en not_active Abandoned
- 2016-08-05 AU AU2016304769A patent/AU2016304769B2/en not_active Ceased
- 2016-08-05 NZ NZ738990A patent/NZ738990A/en not_active IP Right Cessation
- 2016-08-05 RS RS20210803A patent/RS62041B1/sr unknown
- 2016-08-05 BR BR112018000513A patent/BR112018000513A2/pt not_active Application Discontinuation
- 2016-08-05 PE PE2018000215A patent/PE20180655A1/es unknown
- 2016-08-05 US US15/229,249 patent/US9708297B2/en active Active
- 2016-08-05 EA EA201890156A patent/EA201890156A1/ru unknown
- 2016-08-05 LT LTEP16751123.7T patent/LT3334721T/lt unknown
- 2016-08-05 CN CN201680047028.8A patent/CN107922385B/zh active Active
- 2016-08-05 PT PT167511237T patent/PT3334721T/pt unknown
- 2016-08-05 TN TNP/2018/000026A patent/TN2018000026A1/en unknown
-
2017
- 2017-12-25 IL IL256572A patent/IL256572A/en unknown
-
2018
- 2018-01-22 ZA ZA2018/00452A patent/ZA201800452B/en unknown
- 2018-02-01 CL CL2018000290A patent/CL2018000290A1/es unknown
- 2018-02-08 PH PH12018500282A patent/PH12018500282A1/en unknown
- 2018-02-09 EC ECIEPI20189366A patent/ECSP18009366A/es unknown
- 2018-02-09 DO DO2018000042A patent/DOP2018000042A/es unknown
- 2018-02-12 CO CONC2018/0001383A patent/CO2018001383A2/es unknown
- 2018-02-12 SV SV2018005631A patent/SV2018005631A/es unknown
- 2018-06-21 HK HK18107951.2A patent/HK1249095A1/zh unknown
-
2021
- 2021-06-28 HR HRP20211013TT patent/HRP20211013T1/hr unknown
- 2021-06-30 CY CY20211100583T patent/CY1124413T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20211013T1 (hr) | Antagonisti receptora cgrp | |
| HRP20191979T1 (hr) | Heteoarilni spojevi koji su korisni kao inhibitori sumo-aktivirajućeg enzima | |
| HRP20210681T1 (hr) | Kristalne soli (s)-6-((1-acetilpiperidin-4-il)amino)-n-(3-(3,4-dihidroizokinolin-2(1h)-il)-2-hidroksipropil)pirimidin-4-karboksamida | |
| HRP20211011T1 (hr) | N-[4-fluor-5-[[(2s,4s)-2-metil-4-[(5-metil-1,2,4-oksadiazol-3-il)metoksi]-1-piperidil]metil]tiazol-2-il]acetamid kao inhibitor oga | |
| HRP20131051T1 (hr) | Inhibitori proteinskih kinaza | |
| HRP20171696T1 (hr) | 3,4-dihidroizokinolin-2(1h)-ilni spojevi | |
| HRP20170540T1 (hr) | Spojevi dimetilbenzojeve kiseline, korisni u liječenju upalnih stanja | |
| HRP20201949T1 (hr) | 7-benzil-4-(4-(trifluorometil)benzil)-1,2,6,7,8,9-heksahidroimidazo[1,2-a]pirido[3,4-e]pirimidin-5(4h)-on i njegove soli i njihova primjena u terapiji | |
| EA201692095A1 (ru) | Имидазо[4,5-c]хинолин-2-оновые соединения и их применение в лечении рака | |
| HRP20231501T1 (hr) | Derivati benzizoksazolsulfonamida | |
| EP4071149A3 (en) | Heterocyclic compounds and uses thereof | |
| HRP20171151T1 (hr) | Inhibitori cdc7 | |
| WO2017176620A3 (en) | SOLUBLE C5aR ANTAGONISTS | |
| RU2016146119A (ru) | Новый кристалл тетрациклического соединения | |
| HRP20180768T1 (hr) | Triciklički heterociklički spojevi kao inhibitori fosfoinositid-3-kinaze | |
| HRP20190842T1 (hr) | Kristalni oblici 2-((4s)-6-(4-hlorofenil)-1-metil-4h-benzo[c]izoksazolo[4,5-e]azepin-4-il)acetamida | |
| HRP20210655T1 (hr) | Derivati 3-metilpirolidin-2,5-diona korisni kao antagonisti receptora cgrp | |
| HRP20192132T1 (hr) | Antagonist nk-1/nk-3 receptora za liječenje valunga | |
| JP2017509689A5 (hr) | ||
| JP2017514910A5 (hr) | ||
| MA39956A (fr) | Analogues du benzomorphane et leur utilisation | |
| HRP20171515T1 (hr) | Spojevi fenoksietilpiperidina | |
| BR112015018509A2 (pt) | compostos de imidazo piridina | |
| AR116880A1 (es) | Compuestos de pirimidinodiona bicíclicos sustituidos con tetrahidropirano, forma polimórfica del mismo y el uso de los mismos para el tratamiento del hcm | |
| EA202090368A1 (ru) | Соединения-ингибиторы рецептора лизофосфатидной кислоты 1 (lpar1) |